Lewis J. Rubin

60.3k total citations · 18 hit papers
332 papers, 37.9k citations indexed

About

Lewis J. Rubin is a scholar working on Pulmonary and Respiratory Medicine, Cardiology and Cardiovascular Medicine and Genetics. According to data from OpenAlex, Lewis J. Rubin has authored 332 papers receiving a total of 37.9k indexed citations (citations by other indexed papers that have themselves been cited), including 291 papers in Pulmonary and Respiratory Medicine, 151 papers in Cardiology and Cardiovascular Medicine and 56 papers in Genetics. Recurrent topics in Lewis J. Rubin's work include Pulmonary Hypertension Research and Treatments (276 papers), Cardiovascular Issues in Pregnancy (68 papers) and Vascular Anomalies and Treatments (53 papers). Lewis J. Rubin is often cited by papers focused on Pulmonary Hypertension Research and Treatments (276 papers), Cardiovascular Issues in Pregnancy (68 papers) and Vascular Anomalies and Treatments (53 papers). Lewis J. Rubin collaborates with scholars based in United States, France and Germany. Lewis J. Rubin's co-authors include Nazzareno Galiè, David B. Badesch, Gérald Simonneau, Robyn J. Barst, Vallerie V. McLaughlin, Victor F. Tapson, Adaani Frost, Richard N. Channick, Michael D. McGoon and Hossein Ardeschir Ghofrani and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Lewis J. Rubin

325 papers receiving 36.5k citations

Hit Papers

Bosentan Therapy for Pulm... 1990 2026 2002 2014 2002 1996 2009 1997 2004 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Bosentan Therapy for Pulmonary Arterial Hypertension
    2002 2.0k citations Lewis J. Rubin, David B. Badesch et al. profile →
  2. A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension
    1996 2.0k citations Robyn J. Barst, Lewis J. Rubin et al. profile →
  3. ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension
    2009 1.8k citations Vallerie V. McLaughlin, Stephen L. Archer et al. Journal of the American College of Cardiology profile →
  4. Primary Pulmonary Hypertension
    1997 1.4k citations Lewis J. Rubin profile →
  5. Clinical classification of pulmonary hypertension
    2004 1.3k citations Gérald Simonneau, Nazzareno Galiè et al. Journal of the American College of Cardiology profile →
  6. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study
    2001 1.1k citations Richard N. Channick, Olivier Sitbon et al. profile →
  7. Continuous Subcutaneous Infusion of Treprostinil, a Prostacyclin Analogue, in Patients with Pulmonary Arterial Hypertension: A Double-blind, Randomized, Placebo-controlled Trial
    2002 1.1k citations Gérald Simonneau, Robyn J. Barst et al. American Journal of Respiratory and Critical Care Medicine profile →
  8. Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension
    2013 948 citations Tomás Pulido, Richard N. Channick et al. profile →
  9. Riociguat for the Treatment of Pulmonary Arterial Hypertension
    2013 944 citations Hossein Ardeschir Ghofrani, Nazzareno Galiè et al. profile →
  10. Right Ventricular Function and Failure
    2006 924 citations Robyn J. Barst, Michael D. McGoon et al. Circulation profile →
  11. ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension
    2009 844 citations Vallerie V. McLaughlin, Stephen L. Archer et al. Circulation profile →
  12. Ambrisentan for the Treatment of Pulmonary Arterial Hypertension
    2008 785 citations Nazzareno Galiè, Horst Olschewski et al. Circulation profile →
  13. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension
    2015 750 citations Nazzareno Galiè, Adaani Frost et al. profile →
  14. Selexipag for the Treatment of Pulmonary Arterial Hypertension
    2015 706 citations Olivier Sitbon, Richard N. Channick et al. profile →
  15. Chronic Thromboembolic Pulmonary Hypertension
    2001 542 citations Peter F. Fedullo, William R. Auger et al. profile →
  16. Treatment of Primary Pulmonary Hypertension with Continuous Intravenous Prostacyclin (Epoprostenol)
    1990 532 citations Lewis J. Rubin et al. profile →
  17. Updated Treatment Algorithm of Pulmonary Arterial Hypertension
    2013 489 citations Nazzareno Galiè, Adaani Frost et al. Journal of the American College of Cardiology profile →
  18. Randomized Study of Adding Inhaled Iloprost to Existing Bosentan in Pulmonary Arterial Hypertension
    2006 454 citations Vallerie V. McLaughlin, Ronald J. Oudiz et al. American Journal of Respiratory and Critical Care Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lewis J. Rubin United States 89 31.7k 22.0k 6.1k 4.3k 4.1k 332 37.9k
Hossein Ardeschir Ghofrani Germany 86 27.9k 0.9× 17.9k 0.8× 4.5k 0.7× 3.5k 0.8× 5.2k 1.3× 635 34.8k
Robyn J. Barst United States 82 30.6k 1.0× 21.2k 1.0× 6.6k 1.1× 4.0k 0.9× 2.0k 0.5× 250 34.2k
Nazzareno Galiè Italy 76 24.2k 0.8× 17.4k 0.8× 4.7k 0.8× 2.6k 0.6× 2.0k 0.5× 409 27.7k
Olivier Sitbon France 84 24.9k 0.8× 14.8k 0.7× 5.4k 0.9× 3.5k 0.8× 1.8k 0.4× 460 27.7k
David B. Badesch United States 62 23.3k 0.7× 15.2k 0.7× 4.5k 0.7× 3.0k 0.7× 1.9k 0.5× 180 25.9k
Gérald Simonneau France 116 48.1k 1.5× 30.4k 1.4× 10.0k 1.7× 7.9k 1.9× 4.4k 1.1× 567 58.8k
Michael D. McGoon United States 70 22.6k 0.7× 18.2k 0.8× 3.8k 0.6× 4.3k 1.0× 1.4k 0.3× 176 28.5k
Vallerie V. McLaughlin United States 64 19.4k 0.6× 13.5k 0.6× 3.7k 0.6× 2.1k 0.5× 1.4k 0.3× 273 21.5k
Stuart Rich United States 68 19.2k 0.6× 14.3k 0.6× 3.7k 0.6× 3.1k 0.7× 1.2k 0.3× 183 23.1k
Horst Olschewski Austria 69 17.2k 0.5× 10.3k 0.5× 2.4k 0.4× 2.1k 0.5× 2.5k 0.6× 334 21.3k

Countries citing papers authored by Lewis J. Rubin

Since Specialization
Citations

This map shows the geographic impact of Lewis J. Rubin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lewis J. Rubin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lewis J. Rubin more than expected).

Fields of papers citing papers by Lewis J. Rubin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lewis J. Rubin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lewis J. Rubin. The network helps show where Lewis J. Rubin may publish in the future.

Co-authorship network of co-authors of Lewis J. Rubin

This figure shows the co-authorship network connecting the top 25 collaborators of Lewis J. Rubin. A scholar is included among the top collaborators of Lewis J. Rubin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lewis J. Rubin. Lewis J. Rubin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jing, Zhi‐Cheng, Keyur Parikh, Tomás Pulido, et al.. (2013). Efficacy and Safety of Oral Treprostinil Monotherapy for the Treatment of Pulmonary Arterial Hypertension. Circulation. 127(5). 624–633. 242 indexed citations
2.
Sitbon, Olivier, Richard N. Channick, Marion Delcroix, et al.. (2013). Effect of macitentan on haemodynamics in SERAPHIN, a randomised controlled trial in pulmonary arterial hypertension (PAH). European Respiratory Journal. 42(Suppl 57). P4060–P4060. 5 indexed citations
3.
Gomberg‐Maitland, Mardi, Todd M. Bull, Rajeev Saggar, et al.. (2013). New Trial Designs and Potential Therapies for Pulmonary Artery Hypertension. Journal of the American College of Cardiology. 62(25). D82–D91. 98 indexed citations
4.
Grünig, Ekkehard, Nazzareno Galiè, Marc Humbert, et al.. (2013). Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT-1 study. European Respiratory Journal. 42(Suppl 57). 1783–1783. 1 indexed citations
5.
Galiè, Nazzareno, Friedrich Grimminger, Ekkehard Grünig, et al.. (2013). Correlation of improvements in hemodynamics and exercise capacity in patients with PAH: Results from the phase III PATENT-1 study. European Respiratory Journal. 42(Suppl 57). 1784–1784. 5 indexed citations
6.
Bourge, Robert C., Victor F. Tapson, Zeenat Safdar, et al.. (2012). Rapid Transition from Inhaled Iloprost to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension. Cardiovascular Therapeutics. 31(1). 38–44. 29 indexed citations
7.
Clements, Philip J., Mary Tan, Vallerie V. McLaughlin, et al.. (2011). The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH. Annals of the Rheumatic Diseases. 71(2). 249–252. 54 indexed citations
8.
Seibold, James R., Christopher P. Denton, Daniel E. Furst, et al.. (2010). Randomized, prospective, placebo‐controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis & Rheumatism. 62(7). 2101–2108. 104 indexed citations
9.
Kovács, Gábor, Robert Maier, Elisabeth Aberer, et al.. (2009). Borderline Pulmonary Arterial Pressure Is Associated with Decreased Exercise Capacity in Scleroderma. American Journal of Respiratory and Critical Care Medicine. 180(9). 881–886. 112 indexed citations
10.
Badesch, David B., Michael D. McGoon, Victor F. Tapson, et al.. (2009). Longterm Survival Among Patients with Scleroderma-associated Pulmonary Arterial Hypertension Treated with Intravenous Epoprostenol. The Journal of Rheumatology. 36(10). 2244–2249. 59 indexed citations
11.
McLaughlin, Vallerie V., Stephen L. Archer, David B. Badesch, et al.. (2009). ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. Circulation. 119(16). 2250–2294. 844 indexed citations breakdown →
12.
Galiè, Nazzareno, Horst Olschewski, Ronald J. Oudiz, et al.. (2008). Ambrisentan for the Treatment of Pulmonary Arterial Hypertension. Circulation. 117(23). 3010–3019. 785 indexed citations breakdown →
13.
Anthi, Anastasia, Roberto F. Machado, Maria Jison, et al.. (2007). Hemodynamic and Functional Assessment of Patients with Sickle Cell Disease and Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine. 175(12). 1272–1279. 194 indexed citations
14.
McLaughlin, Vallerie V., Ronald J. Oudiz, Adaani Frost, et al.. (2006). Randomized Study of Adding Inhaled Iloprost to Existing Bosentan in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine. 174(11). 1257–1263. 454 indexed citations breakdown →
15.
Peacock, Andrew J., Robert Naeije, & Lewis J. Rubin. (2004). Pulmonary circulation : diseases and their treatment. 41 indexed citations
16.
Rubin, Lewis J. & Nazzareno Galiè. (2004). Pulmonary arterial hypertension: a look to the future. Journal of the American College of Cardiology. 43(12). S89–S90. 30 indexed citations
17.
McLaughlin, Vallerie V., Seán Gaine, Robyn J. Barst, et al.. (2003). Efficacy and Safety of Treprostinil: An Epoprostenol Analog for Primary Pulmonary Hypertension. Journal of Cardiovascular Pharmacology. 41(2). 293–299. 176 indexed citations
18.
Simonneau, Gérald, Robyn J. Barst, Nazzareno Galiè, et al.. (2002). Continuous Subcutaneous Infusion of Treprostinil, a Prostacyclin Analogue, in Patients with Pulmonary Arterial Hypertension: A Double-blind, Randomized, Placebo-controlled Trial. American Journal of Respiratory and Critical Care Medicine. 165(6). 800–804. 1052 indexed citations breakdown →
19.
Bailey, Colleen, Richard N. Channick, William R. Auger, et al.. (2000). “High Probability” Perfusion Lung Scans in Pulmonary Venoocclusive Disease. American Journal of Respiratory and Critical Care Medicine. 162(5). 1974–1978. 68 indexed citations
20.
Reeves, John Τ. & Lewis J. Rubin. (1998). The Pulmonary Circulation: Snapshots of Progress. American Journal of Respiratory and Critical Care Medicine. 157(4). S101–S108. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hossein Ardeschir Ghofrani Breakdown of academic impact, for papers by Robyn J. Barst Breakdown of academic impact, for papers by Nazzareno Galiè Breakdown of academic impact, for papers by Olivier Sitbon Breakdown of academic impact, for papers by David B. Badesch Breakdown of academic impact, for papers by Gérald Simonneau Breakdown of academic impact, for papers by Michael D. McGoon Breakdown of academic impact, for papers by Vallerie V. McLaughlin Breakdown of academic impact, for papers by Stuart Rich Breakdown of academic impact, for papers by Horst Olschewski
Rankless by CCL
2026